background
ep
r
proprietari
aqueousethanol
extract
root
pelargonium
sidoid
dc
demonstr
dispos
among
other
antibacteri
antivir
immunomodulatori
antioxid
tissueprotect
activ
approv
medicin
product
countri
treatment
airway
infect
acut
bronchiti
common
cold
sinus
purpos
pharmacolog
effect
ep
r
extens
evalu
divers
vitro
test
system
number
public
report
result
vivo
model
limit
studi
design
present
studi
antituss
secretolyt
antiinflammatori
effect
ep
r
assess
anim
experi
follow
oral
administr
human
equival
dose
method
antituss
effect
evalu
use
ammoniaand
citric
acidinduc
model
cough
mice
mgkg
guinea
pig
mgkg
respect
determin
secretolyt
activ
tracheobronchi
secret
intraperiton
inject
phenol
red
determin
mice
antiinflammatori
action
assess
acut
bacteri
bronchiti
model
rat
result
signific
dosedepend
reduct
cough
frequenc
observ
cough
model
accompani
prolong
cough
latenc
time
similarli
extract
exert
mark
secretolyt
activ
mice
induct
acut
bacteri
bronchiti
caus
characterist
histopatholog
chang
lung
tissu
adjac
trachea
bronchi
degre
lesion
significantli
reduc
rat
treat
ep
r
dose
mgkg
protect
effect
least
partial
seem
mediat
upregul
superoxid
dismutas
subsequ
protect
effect
oxid
stress
indic
reduc
serum
level
malondialdehyd
conclus
present
data
support
therapeut
use
ep
r
respiratori
tract
infect
provid
basi
detail
studi
bioactiv
constitu
well
vivo
mode
action
southern
africa
differ
indigen
speci
plant
genu
pelargonium
use
folk
medicin
treatment
variou
complaint
diarrhea
dysenteri
liver
disord
dysmenorrhea
centuri
prepar
p
reniform
curti
andor
p
sidoid
dc
also
use
european
herbal
medicin
particularli
therapi
tuberculosi
airway
infect
proprietari
extract
root
p
sidoid
ep
r
develop
regist
full
market
author
abbrevi
sod
superoxid
dismutas
mda
malondialdehyd
sd
standard
deviat
correspond
author
tel
email
address
bao
x
cui
indic
acut
bronchiti
german
feder
institut
drug
medic
devic
brendler
therapeut
efficaci
relat
indic
common
cold
rhinosinus
tonsillopharyng
chronic
obstruct
pulmonari
diseas
evalu
numer
random
doubleblind
placebocontrol
trial
well
observ
clinic
studi
patient
age
one
year
upward
moyo
van
staden
matthi
et
al
safeti
toler
ep
r
demonstr
clinic
trial
postmarket
surveil
studi
involv
adult
children
matthi
et
al
epigalloand
gallocatechin
base
polymer
polyphenol
broad
rang
extens
oxygen
deriv
et
al
vitro
evalu
pharmacolog
activ
reveal
among
other
mild
moder
direct
antibacteri
antivir
properti
inhibit
bacteri
adhes
host
cell
well
activ
innat
immun
defens
later
action
mediat
stimul
releas
tumor
necrosi
factoralpha
nitric
oxid
interferonbeta
accompani
enhanc
natur
killer
cell
activ
improv
phagocytosi
oxid
burst
intracellular
kill
human
peripher
blood
phagocyt
besid
cytoprotect
capabl
increas
ciliari
beat
frequenc
nasal
respiratori
cell
report
kolodziej
pharmacolog
effect
ep
r
extens
investig
divers
vitro
test
system
number
public
report
result
vivo
model
limit
anim
studi
inhibit
lipopolysaccharideinduc
sick
behavior
observ
koch
mild
effect
seen
central
nervou
system
activ
normal
mice
reynold
et
al
addit
antivir
action
ep
r
recent
confirm
mice
inhal
extract
theisen
muller
thu
base
main
clinic
indic
ep
r
present
studi
concentr
evalu
vivo
effect
infect
bronchiti
model
two
common
symptom
relat
airway
infect
ie
cough
disturb
mucociliari
clearanc
investig
perform
singl
batch
pelargonium
sidoid
dri
root
extract
ep
r
kindli
provid
manufactur
dr
willmar
schwabe
pharmaceut
karlsruh
germani
accord
ep
r
standard
dose
mgday
adolesc
adult
bodi
weight
kg
equival
dose
basi
allometr
mean
mice
rat
guinea
pig
would
mgkgday
respect
base
calcul
anim
experi
dose
approxim
correspond
twice
three
time
averag
human
equival
dose
adolesc
person
chosen
henc
follow
dose
appli
mice
mgkgday
rat
mgkgday
guinea
pig
mgkgday
treatment
perform
gavag
ep
r
suspend
distil
water
appli
volum
g
mice
g
rat
guinea
pig
respect
refer
purpos
radix
glycyrrhiza
oral
solut
batch
produc
derun
pharmaceut
co
ltd
beij
employ
product
approv
china
expector
upper
respiratori
tract
infect
bronchiti
cold
cough
radix
glycyrrhiza
oral
solut
contain
licoric
liquid
extract
camphor
tinctur
guaiac
glycerol
ether
previous
shown
activ
experiment
model
use
present
studi
complianc
dose
human
kgday
equival
oral
dose
basi
allometr
mean
mice
mlkgday
rat
mlkgday
guinea
pig
mlkgday
select
male
femal
icr
micespfclass
bodi
weight
g
well
male
femal
wistar
rat
spfclass
bodi
weight
g
provid
beij
vital
river
laboratori
anim
technolog
co
ltd
guinea
pig
male
femal
bodi
weight
g
purchas
beij
jinmuyang
laboratori
anim
breed
co
ltd
anim
kept
standard
environment
condit
h
lightdark
cycl
temperatur
humid
access
standard
feed
tap
water
ad
libitum
allow
least
h
adapt
end
studi
anim
euthan
cervic
disloc
anim
experi
approv
medic
ethic
committe
china
academi
chines
medic
scienc
streptococcu
pneumonia
acquir
chines
pharmaceut
biolog
product
store
c
use
follow
chemic
purchas
supplier
given
bracket
citric
acid
beij
chemic
reagent
compani
batch
total
mice
randomli
distribut
accord
bodi
weight
control
group
radix
glycyrrhiza
group
mlkg
three
ep
r
group
differ
dose
mgkg
treatment
group
consist
mice
equal
number
male
femal
anim
drug
appli
daili
three
consecut
day
gavag
volum
g
control
group
treat
condit
g
distil
water
one
hour
last
treatment
mice
place
contain
volum
l
expos
vapor
ml
concentr
ammonia
anim
remov
quickli
latenc
first
cough
total
number
cough
regist
period
min
rel
cough
latenc
time
calcul
use
follow
formula
rel
cough
latenc
time
cough
latenc
time
sec
test
group
cough
latenc
time
control
group
suitabl
anim
test
select
one
day
experi
guinea
pig
cough
within
min
begin
exposur
spray
citric
acid
solut
cough
less
time
min
observ
period
discard
accord
bodi
weigh
total
select
guinea
pig
randomli
distribut
control
group
radix
glycyrrhiza
group
mlkg
three
ep
r
group
mgkg
group
consist
guinea
pig
equal
number
male
femal
anim
drug
administ
intragastr
day
volum
g
three
consecut
day
control
group
treat
condit
g
distil
water
one
hour
last
dose
guinea
pig
place
contain
volum
l
expos
spray
citric
acid
water
rate
mlmin
produc
nebul
constant
pressur
one
minut
later
latenc
time
begin
spray
first
cough
regist
thereaft
nebul
citric
acid
solut
continu
min
number
cough
subsequ
regist
period
min
rel
cough
latenc
time
calcul
describ
ammoniainduc
cough
mice
phenol
red
excret
mice
total
mice
randomli
distribut
control
group
radix
glycyrrhiza
group
mlkg
three
ep
r
group
mgkg
group
consist
mice
similar
proport
male
femal
anim
drug
appli
gavag
day
volum
g
three
consecut
day
mice
control
group
treat
condit
g
distil
water
thirti
minut
last
dose
mous
receiv
intraperiton
inject
ml
phenol
red
solut
half
hour
later
anim
kill
skin
middl
throat
cut
tissu
surround
trachea
remov
piec
trachea
thyroid
cartilag
tracheal
bifurc
withdrawn
trachea
rins
five
time
ml
nahco
solut
lavag
place
test
tube
phenol
red
concentr
detect
nm
use
spectrophotomet
total
rat
randomli
distribut
accord
bodi
weight
normal
control
group
bronchiti
control
group
radix
glycyrrhiza
group
mlkg
three
ep
r
group
mgkg
except
rat
normal
control
group
anim
place
airtight
glass
contain
fumig
daili
hour
period
day
unburn
smoke
light
cigarett
densiti
gm
addit
rat
treat
intranas
week
total
three
time
ml
streptococcu
pneumonia
begin
day
drug
oral
administr
daili
day
volum
g
anim
normal
model
control
group
treat
condit
g
distil
water
overnight
fast
rat
anesthet
sodium
pentobarbiton
mgkg
intraperiton
day
blood
withdrawn
abdomin
aorta
place
room
temperatur
h
serum
collect
centrifug
min
rpmthen
bronchoalveolar
lavag
fluid
collect
protein
content
bronchoalveolar
lavag
fluid
determin
differenti
cell
count
obtain
lung
remov
subject
histopatholog
examin
follow
criteria
appli
grade
patholog
chang
tracheal
bronchial
epithelium
show
hyperplasia
inflamm
lung
tissu
normal
tracheal
bronchial
epithelium
mild
segment
hyperplasia
inflamm
obviou
pulmonari
interstiti
inflamm
normal
structur
tracheal
bronchial
epithelium
hyperplasia
surround
inflamm
vascular
congest
signific
increas
lymphocyt
interstiti
lung
tissu
tracheal
bronchial
epithelium
signific
hyperplasia
surround
diffus
inflamm
vascular
congest
data
except
result
histopatholog
examin
express
mean
standard
deviat
sd
anova
use
determin
statist
signific
p
pairwis
comparison
group
lsd
test
homogen
varianc
dunett
test
heterogen
varianc
appli
statist
analys
perform
use
spss
softwar
rank
sum
test
use
statist
analysi
histopatholog
examin
inhal
ammonia
vapor
caus
first
cough
respons
control
anim
within
result
total
cough
compar
control
group
cough
frequenc
significantli
dosedepend
reduc
anim
receiv
mgkgday
ep
r
time
cough
latenc
time
prolong
treatment
tabl
antituss
effect
ep
r
confirm
wide
use
second
pharmacolog
model
employ
citric
acidinduc
cough
guinea
pig
comparison
control
group
number
cough
reduc
respect
anim
treat
mgkgday
ep
r
although
mean
cough
latenc
time
markedli
prolong
ep
r
treat
guinea
pig
reach
statist
signific
due
highli
variabl
respons
individu
anim
differ
group
tabl
secretolyt
activ
determin
mice
secret
intraperiton
inject
phenol
red
tracheobronchi
tract
period
min
elimin
dye
via
respiratori
tract
dosedepend
increas
administr
ep
r
three
consecut
day
effect
statist
signific
dose
mgkgday
tabl
valu
mean
sd
p
compar
control
p
compar
control
tabl
valu
mean
sd
p
compar
control
valu
mean
sd
p
compar
control
daili
inhal
unburn
smoke
period
day
combin
weekli
intranas
applic
streptococcu
pneumonia
effect
number
leucocyt
protein
content
bronchoalveolar
lavag
day
compar
normal
control
rat
likewis
paramet
affect
daili
oral
administr
ep
r
mgkgday
day
day
data
shown
howev
histopatholog
examin
reveal
signific
patholog
chang
around
trachea
bronchi
lung
model
group
anim
fig
degre
lesion
trachea
significantli
reduc
rat
treat
ep
r
intermedi
high
dose
tabl
signific
effect
bronchial
histopatholog
seen
tabl
induct
bronchiti
accompani
strong
increas
sod
activ
serum
obvious
regul
defens
mechan
suffici
counteract
possibl
inflammationinduc
oxid
damag
lipid
determin
mda
concentr
serum
interestingli
treatment
rat
ep
r
led
rise
sod
reduct
mda
level
even
healthi
control
anim
tabl
acut
airway
infect
among
common
reason
consult
physician
well
absenc
school
work
due
ill
major
case
respiratori
infect
caus
virus
eg
adenovirus
rhinovirus
influenza
parainfluenza
virus
coronavirus
viru
respiratori
syncyti
viru
coxsacki
virus
usual
selflimit
two
third
case
cure
within
two
week
holzing
et
al
thu
relief
symptom
shorten
diseas
durat
primari
aim
medicin
treatment
viral
infect
respiratori
tract
common
cold
usual
accompani
acut
cough
symptom
includ
sore
throat
runni
nose
headach
grow
pain
fatigu
possibl
fever
transit
common
cold
acut
bronchiti
fluent
earli
stage
inflammatori
reaction
patient
particularli
afflict
dri
cough
follow
releas
inflammatori
mediat
damag
airway
epithelium
sensori
nerv
activ
initi
cough
reflex
although
cough
normal
defens
reflex
keep
respiratori
tract
free
obstruct
harm
substanc
nonproduct
stage
mucu
secret
yet
increas
due
pure
forc
cough
bout
irrit
alreadi
affect
mucou
membran
induc
viciou
circl
thu
antituss
therapi
indic
phase
acut
airway
infect
holzing
et
al
reynold
et
al
although
benefici
therapeut
effect
ep
r
treatment
respiratori
tract
infect
demonstr
great
number
random
control
clinic
trial
well
support
describ
pharmacolog
profil
possibl
antituss
activ
yet
investig
order
simul
situat
earli
stage
acut
bronchiti
dri
nonproduct
cough
induc
chemic
stimul
sensori
nerv
receptor
follow
inhal
ammonia
citric
acid
mice
guinea
pig
respect
result
show
ep
r
therapeut
relev
oral
dose
significantli
cut
cough
frequenc
also
extend
rel
cough
latenc
time
dosedepend
manner
speci
investig
depend
mode
action
medic
use
treatment
cough
usual
classifi
antituss
protuss
antituss
agent
suppress
cough
reflex
peripher
suppress
stimul
sensori
neuron
airway
central
level
cough
center
nucleu
tractu
solitariu
integr
network
reynold
et
al
protuss
compound
improv
effect
cough
improv
expector
airway
secret
increas
volum
secret
secretolyt
lower
viscos
mucu
mucolyt
stimul
mucociliari
clearanc
enhanc
ciliari
activ
mucin
transport
secretomotor
respect
citric
acidsinduc
cough
consider
similar
consciou
guinea
pig
men
report
broad
rang
antituss
well
protuss
drug
observ
activ
model
eg
opioid
local
anesthet
histamin
receptor
antagonist
receptor
agonist
agonist
antimuscarin
expector
mucolyt
current
known
mechan
ep
r
exert
cough
inhibit
action
howev
central
mode
action
may
exclud
ep
r
previous
demonstr
suppress
sick
behavior
coordin
adapt
behavior
develop
infect
respons
central
nervou
action
inflammatori
cytokin
cough
earli
stage
airway
infect
consid
nonproduct
classifi
product
ensu
increas
mucu
product
expector
stimul
airway
secret
first
linedefens
mechan
clear
respiratori
tract
foreign
matter
thu
consid
worthwhil
evalu
ep
r
may
also
effect
tracheobronchi
secret
measur
secretolyt
activ
evalu
measur
excret
phenol
red
respiratori
tract
coppi
gatti
inde
extract
found
dosedepend
increas
elimin
dye
via
respiratori
tract
statist
signific
effect
dose
mgkg
thu
secretolyt
activ
could
also
contribut
cough
inhibit
action
ep
r
dilut
acceler
remov
chemic
stimuli
wherebi
later
effect
may
enhanc
previous
report
increas
ciliari
beat
frequenc
presenc
extract
neugebau
et
al
previous
concern
express
antituss
therapi
combin
applic
protuss
drug
due
possibl
excess
respiratori
secret
may
accumul
airway
howev
modern
treatment
concept
envisag
combin
antituss
secretomucolyt
activ
sinc
respiratori
tract
infect
rare
associ
substanti
mucu
product
ongo
cough
particularli
night
may
extrem
debilit
affect
patient
moric
et
al
besid
benefici
effect
acut
bronchiti
matthi
kamin
ep
r
previous
shown
prolong
time
exacerb
chronic
bronchiti
qualiti
life
patient
chronic
obstruct
pulmonari
diseas
matthi
et
al
thu
present
preclin
studi
vivo
activ
ep
r
oral
applic
supplement
examin
effect
bacteri
bronchiti
rat
well
although
daili
inhal
unburn
smoke
period
day
combin
weekli
intranas
applic
streptococcu
pneumonia
effect
number
leucocyt
protein
content
bronchoalveolar
lavag
histopatholog
examin
clearli
demonstr
ongo
inflammatori
reaction
patholog
chang
dosedepend
reduc
around
trachea
treat
anim
compar
model
control
group
signific
effect
bronchial
histopatholog
seen
dose
mgkg
protect
effect
least
partial
seem
mediat
regul
sod
subsequ
protect
effect
oxid
stress
indic
reduc
serum
level
mda
wide
select
compound
isol
identifi
ep
r
characterist
constitu
extract
highli
oxygen
coumarin
simpl
phenol
eg
catechin
gallocatechin
high
molecular
weight
proanthocyanidin
gener
coumarin
polymer
polyphenol
describ
main
pharmacolog
activ
agent
ep
kolodziej
kolodziej
howev
due
high
degre
polymer
question
proanthocyanidin
may
contribut
pharmacolog
action
ep
r
oral
administr
kolodziej
thu
present
experi
design
investig
antituss
secretolyt
antiinflammatori
effect
ep
r
anim
experi
follow
oral
administr
human
equival
dose
gener
data
definit
support
oral
therapeut
use
ep
r
respiratori
tract
infect
provid
basi
studi
bioactiv
constitu
well
vivo
mode
action
